14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
RADX vs ABSI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Absci Corporation (ABSI) captures the overall head-to-head institutional edge over Radiopharm Theranostics Limited (RADX) on higher Unified Composite conviction (61.0/100 BUY vs. 41.1/100 SELL) after splitting the core matrix 5–2 (led by Growth & Scale, Balance Sheet & Cash Flow), while RADX wins 3–2 across the 6-pillar growth and valuation breakdown. RADX trades at $0.63 (N/M Forward P/E, -411.6% operating margin) versus ABSI at $7.51 (N/M Forward P/E, -9108.3% operating margin).
Growth vs. Quality Trade-Off: ABSI earns the overall head-to-head edge with a stronger Unified Composite Score (61.0/100 BUY vs. RADX 41.1/100 SELL) and 3.18β · 122% Vol risk profile, whereas RADX leads top-line expansion (-36.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: RADX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile ABSI is in a Breakdown options structure phase (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RADX vs ABSI. Trailing 12-month operating profitability (RADX -411.6% vs ABSI -9108.3%) and valuation multiples (RADX N/M vs ABSI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and -9108.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RADX vs ABSI Key Questions & Quantitative Answers
As of Nov 20, 2026, Absci Corporation (ABSI) captures the overall head-to-head institutional edge over Radiopharm Theranostics Limited (RADX) on higher Unified Composite conviction (61.0/100 BUY vs. 41.1/100 SELL) after splitting the core matrix 5–2 (led by Growth & Scale, Balance Sheet & Cash Flow), while RADX wins 3–2 across the 6-pillar growth and valuation breakdown. RADX trades at $0.63 (N/M Forward P/E, -411.6% operating margin) versus ABSI at $7.51 (N/M Forward P/E, -9108.3% operating margin). Growth vs. Quality Trade-Off: ABSI earns the overall head-to-head edge with a stronger Unified Composite Score (61.0/100 BUY vs. RADX 41.1/100 SELL) and 3.18β · 122% Vol risk profile, whereas RADX leads top-line expansion (-36.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RADX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile ABSI is in a Breakdown options structure phase (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABSI leads the Growth & Scale pillar: RADX posts -36.9% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (N/A gross margin, -411.6% operating margin), compared with ABSI at -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin). On trailing 12-month operating scale, RADX generates $13M in USD-normalized revenue versus $1.5M for ABSI. In operating R&D and SG&A reinvestment, RADX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABSI.
RADX screens cheaper on headline valuation multiples. RADX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RADX (-174.7% ROE) versus ABSI (-58.6% ROE) capital efficiency.
In options market volatility and institutional positioning, RADX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 109% Vol realized risk). By comparison, ABSI carries 108.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.80x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.18β · 122% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.